Canaccord Genuity Assumes Travere Therapeutics at Buy, Announces Price Target of $42
Canaccord Genuity analyst Edward Nash assumes Travere Therapeutics (NASDAQ:TVTX) with a Buy rating and announces Price Target of $42.
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
Travere Therapeutics (NASDAQ:TVTX) stock increased by 16.5% to $28.87 during Friday's after-market session. The market value of their outstanding shares is at $1.8 billion.
Travere Therapeutics Announces Presentations Of Abstracts At The 59th ERA Congress
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal Phase 3 PROTECT and DUPLEX studies of sparsentan in IgA nephropathy
Analyst Ratings for Travere Therapeutics
Within the last quarter, Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings:
HC Wainwright & Co. Maintains Buy Rating for Travere Therapeutics: Here’s What You Need To Know
HC Wainwright & Co. has decided to maintain its Buy rating of Travere Therapeutics (NASDAQ:TVTX) and raise its price target from $45.00 to $46.00.
Shares of Travere Therapeutics are trading up 8.5% over the last 24 hours, at $25.54 per share.
FDA Accepts Travere Therapeutics’ NDA for Sparsentan with Priority Review
The U.S. Food and Drug Administration (FDA) has accepted Travere Therapeutics’ (NASDAQ: TVTX) New Drug Application (NDA) under Subpart H and granted Priority Review of sparsentan for the treatment of IgA nephropathy (IgAN).
Travere Therapeutics Announces FDA Acceptance And Priority Review Of New Drug Application For Sparsentan For The Treatment Of IgA Nephropathy
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New Drug Application (NDA) under Subpart H for accelerated approval of
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
Kiromic BioPharma (NASDAQ:KRBP) stock increased by 12.6% to $0.58 during Friday's after-market session. The market value of their outstanding shares is at $8.9 million.
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Earnings Outlook For Retrophin
Retrophin (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Retrophin will report an earnings per share (EPS) of $-0.85.